

## **Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting**

### **Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs**

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company's programs, including an oral presentation on its natural killer (NK) cell product candidate FATE-NK100 as well as multiple poster presentations on its off-the-shelf cancer immunotherapy pipeline, have been accepted for presentation at the 58<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego.

#### **ASH Presentations on Fate Therapeutics' Programs**

##### *FATE-NK100:*

**TITLE:** [Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells \(FATE-NK100\) with Enhanced Anti-Tumor Function](#)

Frank Cichocki

**Publication Number:** 1225

**Session Name:** 711. Cell Collection and Processing: Immunotherapy, Immunomodulation, and Immune Reconstitution

**Date and Time:** Monday, December 5, 2016, 6:15 PM

**Room:** San Diego Convention Center, Room 30

##### *Off-the-Shelf Cancer Immunotherapy:*

**TITLE:** [Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity](#)

Ryan Bjordahl

**Publication Number:** 3363

**Session Name:** 703. Adoptive Immunotherapy: Poster II

**Date and Time:** Sunday, December 4, 2016, 6:00 PM — 8:00 PM

**Location:** San Diego Convention Center, Hall GH

**TITLE:** [Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy](#)

Raedun Clarke

**Publication Number:** 2164

**Session Name:** 703. Adoptive Immunotherapy: Poster I

**Date and Time:** Saturday, December 3, 2016, 5:30 PM - 7:30 PM

**Location:** San Diego Convention Center, Hall GH

**TITLE:** [Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence by Overcoming the Host Histocompatibility Barrier](#)

Raedun Clarke

**Publication Number:** 2165

**Session Name:** 703. Adoptive Immunotherapy: Poster I

**Date and Time:** Saturday, December 3, 2016, 5:30 PM - 7:30 PM

**Location:** San Diego Convention Center, Hall GH

##### *Collaboration with Juno Therapeutics:*

**TITLE:** [Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells](#)

Jonathan Rosen

**Publication Number:** 4712

**Session Name:** 802. Chemical Biology and Experimental Therapeutics: Poster III

**Date and Time:** Monday, December 5, 2016, 6:00 PM - 8:00 PM

**Location:** San Diego Convention Center, Hall GH

ProTmune™:

**TITLE:** [Economic Burden of Acute Graft-Versus-Host Disease \(GvHD\) Following Allogeneic Hematopoietic Cell Transplant \(HCT\) for Hematologic Malignancies](#)

Walter Grubb

**Publication Number:** 1187

**Session Name:** 902. Health Services Research—Malignant Conditions: At the Corner of Cost and Efficacy

**Date and Time:** Monday, December 5, 2016, 5:30 PM

**Room:** San Diego Convention Center, Room 28 A-D

**About Fate Therapeutics, Inc.**

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel *ex vivo* cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

212.362.1200

[christina@sternir.com](mailto:christina@sternir.com)